Onco-Innovations' Nanoparticle Technology Shows Promise in Colorectal Cancer Treatment

Onco-Innovations Limited has announced promising results from studies on its nanoparticle formulation of Polynucleotide Kinase 3'-Phosphatase (PNKP) inhibitors. This technology has demonstrated effectiveness in slowing the growth of colorectal cancer (CRC) tumors both as a standalone treatment and when combined with radiation therapy. The studies were conducted by researchers at the University of Alberta, highlighting the ability of the nanoparticle formulation to specifically target cancer sites.

In standalone treatment, the PNKP inhibitors significantly slowed tumor growth in colorectal cancer-bearing mice. The use of nano-encapsulated PNKP compounds resulted in higher drug levels delivered directly to tumor tissues, proving effective especially in PTEN-deficient CRCs, which are typically more aggressive.

When used with radiation therapy, the nanoparticle formulation also proved successful in slowing tumor growth in mice, showing potential as a sensitization agent in PTEN-positive models. These findings suggest an improvement over conventional treatments, potentially offering new hope for CRC patients.